BAY1187982
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAY1187982, covering 2017-07-12 to 2017-07-12. Get the full timeline:
Most recent: Clinical Trial Update: Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) [Phase 1]